In last trading session, Kiora Pharmaceuticals Inc. (NASDAQ:KPRX) saw 0.14 million shares changing hands with its beta currently measuring 0.38. Company’s recent per share price level of $3.71 trading at $0.3 or 8.80% at ring of the bell on the day assigns it a market valuation of $6.60M. That closing price of KPRX’s stock is at a discount of -1829.92% from its 52-week high price of $71.60 and is indicating a premium of 13.48% from its 52-week low price of $3.21. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.49 million shares which gives us an average trading volume of 678.44K if we extend that period to 3-months.
For Kiora Pharmaceuticals Inc. (KPRX), analysts’ consensus is at an average recommendation of an Overweight while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$3.83 in the current quarter.
Kiora Pharmaceuticals Inc. (NASDAQ:KPRX) trade information
Upright in the green during last session for gaining 8.80%, in the last five days KPRX remained trading in the red while hitting it’s week-highest on Thursday, 11/17/22 when the stock touched $3.71 price level, adding 50.47% to its value on the day. Kiora Pharmaceuticals Inc.’s shares saw a change of -93.86% in year-to-date performance and have moved -37.12% in past 5-day. Kiora Pharmaceuticals Inc. (NASDAQ:KPRX) showed a performance of -45.20% in past 30-days. Number of shares sold short was 81940.0 shares which calculate 0.17 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $259.50 to the stock, which implies a rise of 98.57% to its current value. Analysts have been projecting $119.00 as a low price target for the stock while placing it at a high target of $400.00. It follows that stock’s current price would drop -10681.67% in reaching the projected high whereas dropping to the targeted low would mean a loss of -3107.55% for stock’s current value.
Kiora Pharmaceuticals Inc. (KPRX) estimates and forecasts
Statistics highlight that Kiora Pharmaceuticals Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -75.82% of value to its shares in past 6 months, showing an annual growth rate of 72.29% while that of industry is 11.30. Apart from that, the company came raising its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to increase by 67.00% in the current quarter and calculating 83.60% increase in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 42.50% during past 5 years.
Kiora Pharmaceuticals Inc. is more likely to be releasing its next quarterly report between November 14 and November 18 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Kiora Pharmaceuticals Inc. (NASDAQ:KPRX)’s Major holders
Insiders are in possession of 12.39% of company’s total shares while institution are holding 6.98 percent of that, with stock having share float percentage of 7.97%. Investors also watch the number of corporate investors in a company very closely, which is 6.98% institutions for Kiora Pharmaceuticals Inc. that are currently holding shares of the company. Geode Capital Management, LLC is the top institutional holder at KPRX for having 13678.0 shares of worth $0.26 million. And as of Jun 29, 2022, it was holding 0.04% of the company’s outstanding shares.
On the other hand, Fidelity NASDAQ Composite Index ETF and Fidelity Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 29, 2022, the former fund manager was holding 7292.0 shares of worth $44845.0 or 0.02% of the total outstanding shares. The later fund manager was in possession of 3125.0 shares on Jun 29, 2022, making its stake of worth around $58825.0 in the company or a holder of 0.01% of company’s stock.